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A BS T R AC T
Background

Eltrombopag is a new, orally active thrombopoietin-receptor agonist that stimulates
thrombopoiesis. We evaluated its ability to increase platelet counts and facilitate
treatment for hepatitis C virus (HCV) infection in patients with thrombocytopenia
associated with HCV-related cirrhosis.
Methods

Seventy-four patients with HCV-related cirrhosis and platelet counts of 20,000 to
less than 70,000 per cubic millimeter were randomly assigned to receive eltrombopag
(30, 50, or 75 mg daily) or placebo daily for 4 weeks. The primary end point was a
platelet count of 100,000 per cubic millimeter or more at week 4. Peginterferon and
ribavirin could then be initiated, with continuation of eltrombopag or placebo for
12 additional weeks.
Results

At week 4, platelet counts were increased to 100,000 per cubic millimeter or more
in a dose-dependent manner among patients for whom these data were available:
in 0 of the 17 patients receiving placebo, in 9 of 12 (75%) receiving 30 mg of eltrombo
pag, in 15 of 19 (79%) receiving 50 mg of eltrombopag, and in 20 of 21 (95%) receiving 75 mg of eltrombopag (P<0.001). Antiviral therapy was initiated in 49 patients
(in 4 of 18 patients receiving placebo, 10 of 14 receiving 30 mg of eltrombopag, 14 of
19 receiving 50 mg of eltrombopag, and 21 of 23 receiving 75 mg of eltrombopag)
while the administration of eltrombopag or placebo was continued. Twelve weeks
of antiviral therapy, with concurrent receipt of eltrombopag or placebo, were completed by 36%, 53%, and 65% of patients receiving 30 mg, 50 mg, and 75 mg of
eltrombopag, respectively, and by 6% of patients in the placebo group. The most
common adverse event during the initial 4 weeks was headache; thereafter, the adverse events were those expected with interferon-based therapy.

From Duke University and Duke Clinical
Research Institute, Durham, NC (J.G.M.);
Royal Free Hospital, London (G.D.); Virginia Commonwealth University Medical
Center, Richmond (M.L.S.); Fundación de
Investigación de Diego, San Juan, Puerto
Rico (M.R.-T.); Weill Medical College of
Cornell University, New York (S.S.); Hôpital Saint Joseph, Marseille, France (M.B.);
Charité, Berlin (T.B.); Henry Ford Hospital and Health System, Detroit (S.C.G.);
GlaxoSmithKline, Greenford, United Kingdom (F.M.C.); GlaxoSmithKline, Research
Triangle Park, NC (D.T.); GlaxoSmithKline,
Philadelphia (N.B., J.J.); and Beth Israel Dea
coness Medical Center, Boston (N.H.A.).
Address reprint requests to Dr. McHutchison at Duke University and Duke Clinical
Research Institute, P.O. Box 17969, Durham,
NC 27705, or at mchut001@mc.duke.edu.
*The members of the TPL102357 Study
Group are listed in the Appendix.
N Engl J Med 2007;357:2227-36.
Copyright © 2007 Massachusetts Medical Society.

Conclusions

Eltrombopag therapy increases platelet counts in patients with thrombocytopenia
due to HCV-related cirrhosis, thereby permitting the initiation of antiviral therapy.
(ClinicalTrials.gov number, NCT00110799.)
n engl j med 357;22
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T

hrombocytopenia is a frequent
complication of chronic liver disease and
is considered an indicator of advanced disease.1-3 The low platelet count is due partly to the
effects of portal hypertension and hypersplenism,4 decreased thrombopoietin production,2,5,6
and virus-induced bone marrow suppression.7,8
Patients with chronic liver disease due to infection with the hepatitis C virus (HCV) who have
thrombocytopenia (<75,000 platelets per cubic
millimeter) have been routinely excluded from
clinical trials of interferon and ribavirin, and few
published reports have described the treatment of
chronic HCV infection in patients with platelet
counts of less than 50,000 per cubic millimeter.
Although a reduced platelet count is not an absolute contraindication to treatment with pegylated
interferon (peginterferon) and ribavirin, product la
bels advise that caution be used in treating patients
with clinically significant thrombocytopenia. Fur
thermore, if thrombocytopenia develops during
antiviral therapy, peginterferon may need to be
delivered at a reduced dose or discontinued.9,10
Currently, there is no approved treatment for throm
bocytopenia in patients with HCV infection.
Eltrombopag (SB-497115, GlaxoSmithKline) is
a new, small-molecule, nonpeptide, oral platelet
growth factor that acts as a thrombopoietin-recep
tor agonist. The drug interacts with the transmembrane domain of the thrombopoietin receptor and induces proliferation and differentiation
of megakaryocytes and, as a result, an increase in
platelet production. In preclinical and early clinical studies, eltrombopag therapy was shown to
stimulate megakaryocyte proliferation and differ
entiation and to cause dose-dependent increases
in platelet counts in chimpanzees and humans.11‑14
Ex vivo experiments with platelets from humans
and in vivo studies of healthy subjects have shown
that treatment with eltrombopag does not adversely affect platelet function.15,16 Eltrombopag
has also been shown to increase platelet counts
in a dose-dependent manner in patients with
chronic immune thrombocytopenic purpura.17
In this phase 2 study, we assessed whether the
use of eltrombopag can increase platelet counts
in patients with thrombocytopenia associated
with cirrhosis due to chronic HCV infection. The
safety and adverse-event profiles of eltrombopag
were also evaluated.
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Me thods
Patients

Patients were enrolled from 22 centers in the
United States and Europe. Eligible patients were
18 years of age or older and had chronic HCV
infection (defined as the presence of anti-HCV
antibodies and detectable serum HCV RNA levels,
as determined with the use of a clinically available assay chosen by the investigator), compensat
ed liver disease, and thrombocytopenia (defined
as a platelet count of 20,000 to <70,000 per cubic
millimeter). Patients were also required to have a
liver-biopsy specimen indicative of cirrhosis, radio
graphic evidence of cirrhosis, or endoscopic evidence of portal hypertension. Patients were excluded if they were pregnant, had a history of
thrombosis, or were coinfected with the human
immunodeficiency virus or the hepatitis B virus.
Our study was approved by the institutional
review board or ethics committee at each participating center and was conducted in accordance
with the provisions of the Declaration of Helsinki,
Good Clinical Practice guidelines, and local laws
and regulations. All patients provided written informed consent.
Study Design and Organization

Our study was an international, multicenter, double-blind, randomized, placebo-controlled, phase 2
trial covering a range of doses of eltrombopag.
After meeting the eligibility criteria, patients were
randomly assigned to study groups in a 1:1:1:1
ratio with the use of permuted-block randomization and a block size of four. The random assignment was stratified according to the baseline plate
let count (20,000 to <50,000 per cubic millimeter
vs. 50,000 to <70,000 per cubic millimeter). Patients were assigned to an eltrombopag group or
the placebo group by means of central randomization, which was independent of the study centers
and involved an interactive voice system. In the
initial treatment phase, patients received either el
trombopag tablets, once daily, at a dose of 30 mg,
50 mg, or 75 mg or matching placebo, once daily,
for 4 weeks (Fig. 1). Hematologic, biochemical,
and other safety assessments were performed
weekly. Treatment with eltrombopag was interrupted if the platelet count was 200,000 or more
per cubic millimeter; treatment was then reinstat-
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74 Patients were randomly assigned
to a study group

Initial Treatment Phase
14 Received 30 mg
of eltrombopag

18 Received placebo

19 Received 50 mg
of eltrombopag

23 Received 75 mg
of eltrombopag

Antiviral Treatment Phase
(peginterferon+eltrombopag
or placebo)
4 Did not receive
peginterferon
1 Owing to an
adverse event
2 For personal
reasons
1 For unspecified
reasons

14 Did not receive
peginterferon
2 For personal
reasons
7 Owing to lack
of efficacy
5 For unspecified
reasons
4 Received
peginterferon

10 Received
peginterferon

1 Completed 12 wk
of peginterferon therapy

14 Received
peginterferon

5 Did not complete
12 wk of peginterferon
therapy
2 Owing to an
adverse event
1 Owing to loss
to follow-up
1 For personal
reasons
1 For unspecified
reasons

3 Did not complete
12 wk of peginterferon
therapy
1 Owing to lack
of efficacy
2 For unspecified
reasons

5 Did not receive
peginterferon
2 For personal
reasons
2 Owing to lack
of efficacy
1 For unspecified
reasons

5 Completed 12 wk
of peginterferon therapy

4 Did not complete
12 wk of peginterferon
therapy
1 Owing to an
adverse event
1 Owing to lack
of efficacy
1 For personal
reasons
1 For unspecified
reasons

10 Completed 12 wk
of peginterferon therapy

2 Did not receive
peginterferon
1 Owing to lack
of efficacy
1 For unspecified
reasons

21 Received
peginterferon

6 Did not complete
12 wk of peginterferon
therapy
1 Owing to an
adverse event
1 Owing to loss
to follow-up
4 For unspecified
reasons

15 Completed 12 wk
of peginterferon therapy

Figure 1. Randomization and Follow-up of the Study Patients.
In the initial treatment phase, patients received eltrombopag (30, 50, or 75 mg) or placebo daily for 4 weeks. Hematologic and safety
assessments were performed weekly during this phase. After 4 weeks, antiviral therapy
for 121st
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ed on an individual basis, generally when platelet
counts returned to 100,000 or less per cubic millimeter.
Patients who completed the initial treatment
phase were eligible for antiviral treatment if they
had attained a predefined platelet count: 70,000
or more per cubic millimeter for the use of peg
interferon alfa-2a (Pegasys, Roche) or 100,000 or
more per cubic millimeter for the use of peginterferon alfa-2b (Peg-Intron, Schering-Plough). The
choice of interferon was not dictated by the proto
col but rather was at the investigator’s discretion.
In this antiviral treatment phase, peginterferon
(180 μg of peginterferon alfa-2a per week or 1.5
μg of peginterferon alfa-2b per kilogram of body
weight per week) and ribavirin (1000 to 1200 mg
per day for patients receiving peginterferon alfa2a and 800 mg per day for those receiving peginterferon alfa-2b) were administered for 8 weeks
concomitantly with eltrombopag or placebo. Once
additional preclinical safety data were available,
the protocol was amended to extend this phase to
12 weeks, at which time eltrombopag was stopped
and antiviral therapy was continued at the investigator’s discretion. A follow-up visit was scheduled for 4 weeks after the last dose of eltrombopag or placebo had been received. Throughout
the antiviral treatment phase, in accordance
with the product labels for these approved therapies, the dose of peginterferon alfa-2a was reduced by half if the platelet count had decreased
to 25,000 to 50,000 per cubic millimeter and was
discontinued altogether if the platelet count was
below 25,000 per cubic millimeter. The dose of
peginterferon alfa-2b was reduced by half if the
platelet count had decreased to 50,000 to 80,000
per cubic millimeter and was discontinued altogether if the platelet count was less than 50,000
per cubic millimeter.
An independent data monitoring committee
was established to review data during the study.
A separate independent committee reviewed all
ophthalmic evaluations, because ocular findings
in preclinical studies of immature rodents indicat
ed a risk of cataract formation.
The sponsor, GlaxoSmithKline, and the academic principal investigator designed the study,
developed the protocol, and prepared the first and
subsequent drafts of the manuscript, with input
from participating academic investigators. The
sponsor and the academic principal investigator
held and analyzed the data. Decisions related to
2230
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the content of the final draft of the manuscript
were made by the academic principal investigator
in consultation with all coauthors. All authors,
four of whom are employees of GlaxoSmithKline,
had access to the data and contributed to the writing of the manuscript. The academic principal investigator vouches for the completeness and accuracy of this article.
Statistical Analysis

The primary efficacy end point was an increase in
the platelet count from the baseline value (20,000
to <70,000 per cubic millimeter) to 100,000 or
more per cubic millimeter after the 4-week initial
treatment phase. Secondary end points included
those related to safety, tolerability, and the ability
to continue peginterferon therapy during the antiviral treatment phase. The analyses included all
patients who were randomly assigned to a study
group and who received at least one dose of the
study medication. In the analysis of the primary
end point, however, data for 5 of the 74 patients
(7%) who entered the study but whose baseline
platelet count was 70,000 or more per cubic milli
meter were excluded; missing data were imputed
with the use of the last-observation-carried-forward approach.
We planned to enroll 160 patients in the study,
with 40 patients randomly assigned to each study
group. We estimated the number of patients assuming a rate of response of 20% in the placebo
group and 60% in the three active treatment
groups. The power of our study to detect this
anticipated treatment effect was 90% at an overall
two-sided level of significance of 5%. The primary
end point was analyzed with the use of multiple
logistic-regression analysis. Each of the three eltrombopag groups was compared with the place
bo group by means of a closed testing procedure.
We tested the global null hypothesis of no significant difference among the four study groups
and, if this global hypothesis was rejected, the
null hypothesis of no significant difference between the placebo group and each eltrombopag
group, with testing performed in the predetermined order of the highest dose (75 mg) to the
lowest dose (30 mg). The sequential testing was
continued until the null hypothesis could not be
rejected.
The study was originally planned to be performed without interim analyses, except for a
blinded review by the independent data monitor-
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ing committee of the safety and adverse-event
profiles after 40 patients had completed the initial treatment phase. A subsequent amendment
to the protocol stipulated the performance of formal interim analyses of efficacy data from the
initial treatment phase.
The criterion for stopping the study early was
a two-sided P value no greater than 0.0001, based
on the O’Brien–Fleming adjustment for a groupsequential design, from an interim analysis of the
efficacy data.18 The criterion was not met in the
first interim analysis but was met in the second
interim analysis (overall comparison for the four
study groups, P<0.0001; 30 mg of eltrombopag vs.
placebo, P = 0.00067; 50 mg of eltrombopag vs.
placebo, P = 0.00015; and 75 mg of eltrombopag
vs. placebo, P<0.0001).

R e sult s
Characteristics of the Patients

Between April 5, 2005, and October 20, 2006, a
total of 74 patients were randomly assigned to a
study group and received the study drug or placebo (Fig. 1): 18 patients received placebo, 14 received 30 mg of eltrombopag, 19 received 50 mg
of eltrombopag, and 23 received 75 mg of eltrombopag. Since the 74 patients were distributed across
22 sites, some sites did not use a complete block,
which caused a slight imbalance in the numbers
of patients assigned to the four groups. The demographic and baseline clinical characteristics of the
study groups were well balanced (Table 1). The
median age was 51 years (range, 30 to 74), and
more than two thirds of the patients were men.

Table 1. Baseline Characteristics of the Patients.*
Characteristic

Eltrombopag
30 mg (N = 14)

Age — yr

50 mg (N = 19)

Placebo (N = 18)

All (N = 74)

75 mg (N = 23)

Median

56

50

51

52

51

Range

43–74

30–72

38–60

41–71

30–74

10 (71)

12 (63)

19 (83)

11 (61)

52 (70)

4 (29)

7 (37)

4 (17)

7 (39)

22 (30)

0

2 (11)

1 (4)

1 (6)

4 (5)

Sex — no. (%)
Male
Female
Race — no. (%)†
Black
Asian

0

White

1 (5)

13 (93)

0

16 (84)

22 (96)

1 (6)

2 (3)

16 (89)

67 (91)

Platelet count
Median — per mm3

59,000

52,000

54,000

55,000

55,000

Range — per mm3

34,000–94,000

26,000–66,000

28,000–75,000

27,000–75,000

26,000–94,000

20,000 to <50,000/mm3 — no. (%)

5 (36)

7 (37)

8 (35)

6 (33)

26 (35)

<70,000/mm3

7 (50)

12 (63)

13 (57)

11 (61)

43 (58)

2 (9)

1 (6)

5 (7)

≥50,000 to

— no. (%)

≥70,000/mm3 — no. (%)

2 (14)

0

HCV genotype — no. (%)
1 or 4

10 (71)

11 (58)

14 (61)

10 (56)

45 (61)

2 or 3

4 (29)

8 (42)

8 (35)

7 (39)

27 (36)

Unknown

0

Albumin — g/liter

0

35.8±6.8

33.8±4.9

1 (4)

1 (6)

2 (3)

36.6±5.7

36.4±5.8

35.7±5.7

Alanine aminotransferase — IU/liter

120.6±51.4

117.8±67.5

117.0±69.3

120.5±70.7

118.8±64.2

Aspartate aminotransferase — IU/liter

123.3±68.1

127.4±67.3

128.6±104.1

129.5±72.8

127.5±79.2

25.3±11.5

25.1±14.1

24.9±16.3

27.7±14.0

25.7±14.4

Total bilirubin — µmol/liter

* Plus–minus values are means ±SD. There were no significant differences in characteristics between the study groups. HCV denotes hepatitis C virus. To convert values for total bilirubin to milligrams per deciliter, divide by 17.1.
† Race was self-reported; data were not available for one patient.
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The median baseline platelet count was 55,000
per cubic millimeter (range, 26,000 to 94,000).
The baseline platelet count was 20,000 to less
than 50,000 per cubic millimeter in 35% of patients (26 of 74) and 50,000 to less than 70,000
per cubic millimeter in 58% (43 of 74) (Table 1).
Seven percent of patients (5 of 74) who were successfully screened had baseline platelet counts of
70,000 or more per cubic millimeter just before
administration of the study drug, which was considered a violation of the protocol. Therefore, the
data for these five patients were excluded from
the analysis of the primary efficacy end point,
but they were included in the safety analysis because the patients received the study drug.
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Efficacy

Initial Treatment Phase

The receipt of eltrombopag increased platelet
counts to 100,000 or more per cubic millimeter at
week 4, in a dose-dependent manner (P<0.001 for
overall treatment effect) (Table 2). The effect of
each dose of eltrombopag was significant (P<0.001),
as compared with the effect of placebo. No patient
in the placebo group had an increase in the platelet count to 100,000 or more per cubic millimeter
after 4 weeks. The results for the primary end
point based on the observed data only (i.e., those
obtained without the application of the last-observation-carried-forward approach) were similar to
the results when the last-observation-carried-for-

Table 2. Median Platelet Counts at the End of the Initial Treatment Phase and the End of the Antiviral Treatment Phase.*
Variable

Eltrombopag
30 mg (N = 14)

50 mg (N = 19)

Placebo (N = 18)
75 mg (N = 23)

End of initial treatment phase
Platelet count
No. of patients with data

11

16

22

14

Median — per mm3

125,000

212,000

204,000

53,000

Range — per mm3

40,000 to 214,000

47,000 to 599,000

78,000 to 527,000

34,000 to 74,000

Change from baseline
No. of patients with data

12

16

22

14

Median — per mm3

74,000

152,000

151,000

−3,000

Range — per mm3

6,000 to 155,000

10,000 to 540,000

45,000 to 473,000

−22,000 to 13,000

≥100,000/mm3

— no. of responders/total no.
of patients who could be evaluated (%)

9/12 (75)

15/19 (79)

20/21 (95)

0/17

≥200,000/mm3 — no. of responders/total no.
of patients who could be evaluated (%)

3/12 (25)

9/19 (47)

11/21 (52)

0/17

2

7

8

1

106,000

100,000

92,000

39,000

43,000 to 164,000

46,000 to 156,000

38,000 to 245,000

39,000 to 39,000

End of antiviral treatment phase
Platelet count
No. of patients with data
Median — per
Range — per

mm3

mm3

Change from baseline — per mm3
Median

31,000

54,000

31,000

Range

−18,000 to 122,000

8000 to 97,000

−23,000 to 191,000

−25,000
−25,000 to −25,000

* Data were not available for some patients because of withdrawal from the study before week 4 or for other reasons. Patients who could
be evaluated were those whose data were included in the last-observation-carried-forward analysis in the intention-to-treat population and
excluded those with a platelet count of less than 20,000 per cubic millimeter or 70,000 or more per cubic milliliter at baseline or those for
whom the platelet count was unknown during the antiviral treatment phase. The overall P value for the treatment effect at the end of the
initial treatment phase was less than 0.001, as were the P values for the comparison of each eltrombopag group with the placebo group
with respect to the percentages of patients with platelet counts of 100,000 or more per cubic millimeter at the end of the initial treatment
phase.
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ward approach was used. Between 25 and 52% of
patients receiving eltrombopag (primarily those re
ceiving 50-mg or 75-mg doses daily) had platelet
counts of 200,000 or more per cubic millimeter at
any time during the initial treatment phase. Treatment with eltrombopag was interrupted in these
patients until their platelet counts decreased to
100,000 or fewer per cubic millimeter.

per cubic millimeter during this phase. No patient in the placebo group had a platelet count
this high while receiving antiviral therapy. In the
initial or antiviral treatment phase, platelet counts
exceeded the protocol-specified upper limit of
200,000 per cubic millimeter in at least one visit
in 4 of 14 patients (29%), 9 of 19 (47%), and 16 of
23 (70%) in the groups receiving 30 mg of eltrombopag, 50 mg of eltrombopag, and 75 mg of
Antiviral Treatment Phase
eltrombopag, respectively, necessitating a tempoOverall, two thirds of the patients (49 of 74) pro- rary interruption in eltrombopag therapy.
ceeded to the antiviral treatment phase: 4 of the
18 patients (22%) receiving placebo and 10 of the Safety
14 (71%), 14 of the 19 (74%), and 21 of the 23 (91%) During the 4-week initial treatment phase, headreceiving 30 mg, 50 mg, and 75 mg of eltrom- ache was reported in 36%, 16%, and 17% of pabopag, respectively (Fig. 1). Of these 49 patients, tients who received 30 mg of eltrombopag, 50 mg
48 had a platelet count that met the prespecified of eltrombopag, and 75 mg of eltrombopag, respec
threshold for entry into the antiviral treatment tively, as well as in 17% of patients who received
phase (≥70,000 per cubic millimeter for the use placebo (Table 3). Other common adverse events
of peginterferon alfa-2a or ≥100,000 per cubic in the three eltrombopag groups were dry mouth,
millimeter for the use of peginterferon alfa-2b), abdominal pain, and nausea.
and therefore peginterferon-based therapy could
During the subsequent antiviral treatment
be initiated (Fig. 1).
phase, the incidence of adverse events was simiOn an intention-to-treat basis, the first 12 lar in all three eltrombopag groups. The adverse
weeks of antiviral therapy were completed by 5 of events most commonly reported during this phase
14 patients receiving 30 mg of eltrombopag were influenza-like illness, fatigue, chills, and
(36%), 10 of 19 receiving 50 mg (53%), and 15 of headache, all of which are known side effects of
23 receiving 75 mg (65%), as compared with 1 of interferon-based therapy.19,20
18 patients (6%) in the placebo group (Fig. 2).
Drug-related adverse events were reported for
Platelet counts in all eltrombopag groups de- five patients receiving 30 mg of eltrombopag
creased during the antiviral treatment phase, (36%), eight receiving 50 mg (42%), and eight re
despite continued treatment with eltrombopag, ceiving 75 mg (35%), as compared with three pa
but remained consistently above baseline values, tients (17%) in the placebo group. The most frewith a nadir of more than 50,000 per cubic milli quent drug-related adverse events (all of low-grade
meter (Table 2 and Fig. 2). Among the patients severity) were dry mouth, headache, and nausea.
who completed the 12-week antiviral treatment After treatment had been discontinued, thrombophase and for whom platelet counts were avail- cytopenia occurred in one patient receiving 30 mg
able, a platelet count greater than the baseline of eltrombopag, decreased visual acuity occurred
value was maintained after completion of the in another receiving 30 mg of eltrombopag, and
antiviral treatment phase in 0 of 1 patient receiv- petechiae occurred in one patient receiving 75 mg
ing placebo, 4 of 5 receiving 30 mg of eltrombo of eltrombopag.
pag, 4 of 5 receiving 50 mg of eltrombopag, and
During the entire study, 62 patients reported
10 of 12 receiving 75 mg of eltrombopag.
adverse events and 7 reported serious adverse
At all time points during the antiviral treat- events. These serious events included ascites (in
ment phase, platelet counts in all three eltrombo the group receiving 30 mg of eltrombopag), which
pag groups were higher than those in the place subsequently resolved, and retinal exudates (in
bo group and remained higher than the level at the group receiving 75 mg of eltrombopag), which
which a reduction in the peginterferon dose is did not resolve and which were deemed by the
recommended (<50,000 per cubic millimeter). In investigator to be unrelated to treatment with
the group receiving 75 mg of eltrombopag, 18 of eltrombopag. Thrombocytopenia in one patient
21 patients had platelet counts of 50,000 or more receiving 30 mg of eltrombopag and myositis in
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one patient receiving 50 mg of eltrombopag were
resolving at the end of the study. The thrombocytopenia occurred after eltrombopag therapy had
been discontinued and peginterferon administration had begun; the platelet count fell below the
patient’s baseline count, and the event was considered by the investigator to be related to the
study drug. One patient in the placebo group had
2234
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two reported serious adverse events, abdominal
pain and renal failure, and subsequently died.
Adverse events led to the withdrawal of three
patients receiving 30 mg of eltrombopag (owing
to upper abdominal pain and ascites), one patient
receiving 50 mg of eltrombopag (owing to neutropenia), and one patient receiving 75 mg of eltrombopag (owing to retinal exudates).
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Table 3. Most Common Adverse Events during the Initial Treatment Phase and the Antiviral Treatment Phase.*
Event

Eltrombopag
30 mg (N = 14)

50 mg (N = 19)

Placebo (N = 18)
75 mg (N = 23)

number of events (percent)

Initial treatment phase
Any

11 (79)

10 (53)

13 (57)

10 (56)

Headache

5 (36)

3 (16)

4 (17)

3 (17)

Dry mouth

2 (14)

2 (11)

2 (9)

1 (6)

Upper abdominal pain

2 (14)

2 (11)

0

0

Nausea

1 (7)

2 (11)

1 (4)

0

Any

9 (64)

13 (68)

17 (74)

3 (17)

Influenza-like illness

4 (29)

5 (26)

8 (35)

1 (6)

Fatigue

4 (29)

5 (26)

5 (22)

1 (6)

Chills

0

6 (32)

2 (9)

1 (6)

Headache

3 (21)

3 (16)

3 (13)

0

Arthralgia

3 (21)

1 (5)

2 (9)

1 (6)

Antiviral treatment phase

Depression

2 (14)

1 (5)

4 (17)

0

Myalgia

3 (21)

2 (11)

2 (9)

0

Nausea

3 (21)

3 (16)

1 (4)

0

Anemia

2 (14)

2 (11)

2 (9)

0

Pyrexia

1 (7)

3 (16)

2 (9)

0

Diarrhea

0

1 (5)

3 (13)

1 (6)

Irritability

2 (14)

0

1 (4)

1 (6)

Pruritus

1 (7)

2 (11)

0

1 (6)

Rash

0

3 (16)

1 (4)

0

* The adverse events listed are those that occurred in more than 3% of patients in any group.

Dis cus sion
Thrombocytopenia in patients with cirrhosis due
to HCV can prevent or limit antiviral treatment,
but there is little information concerning the eligibility for treatment of patients with platelet
counts of less than 50,000 per cubic millimeter.
In our study, 30 of 45 patients who had had a
response to eltrombopag, with a rise in the platelet count to 70,000 or more per cubic millimeter
(or ≥100,000 per cubic millimeter) during the initial treatment phase, completed the first 12 weeks
of antiviral treatment with peginterferon, during
which time the use of eltrombopag was continued; specifically, 65% of those receiving 75 mg of
eltrombopag and 53% of those receiving 50 mg
of eltrombopag completed the first 12 weeks of
the treatment.
n engl j med 357;22

The most common side effects of eltrombopag
during the initial treatment phase were headache, dry mouth, abdominal pain, and nausea;
these effects were of insufficient severity to require discontinuation of the drug. In this small
and therefore underpowered study, we did not
find evidence of a dose–response relation with
respect to the occurrence of adverse events in the
antiviral treatment phase, during which the reported side effects were consistent with those
associated with interferon-based therapy.
During the initial treatment phase, significant
increases in platelet counts were observed in each
of the three eltrombopag groups as compared
with the placebo group. The primary end point
(a platelet count ≥100,000 per cubic millimeter at
week 4) was met in 75 to 95% of patients in the
eltrombopag groups, in a dose-dependent man-
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ner. During the subsequent antiviral phase, platelet counts decreased, perhaps owing to the antiplatelet effect of peginterferon; nevertheless,
platelet counts remained consistently above baseline levels. These results require confirmation in
phase 3 trials involving standard-duration courses
of peginterferon and ribavirin.
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